F-1/A: Anbio Biotechnology Files for IPO: Supply Agreement and Financial Details Revealed

Anbio Biotechnology's F-1/A filing details a supply agreement and key financial information as the company prepares for its initial public offering.

Summary

• Anbio Biotechnology, a Cayman Islands-based company, has filed an F-1/A registration statement.
• The document includes a supply agreement between Anbio Biotechnology Limited and an unnamed supplier, outlining terms for product supply and distribution.
• The agreement covers product specifications, pricing, purchase orders, shipping, quality assurance, and intellectual property rights.
• It also includes clauses on confidentiality, indemnification, and termination.
• The company is offering 1,600,000 Class A ordinary shares with an anticipated initial public offering price between US$5.00 and US$6.00 per share.
• Upon completion of the offering, the company's outstanding shares will consist of 43,891,200 Class A Ordinary Shares and 100,000,000 Class B Ordinary Shares.
• The company intends to use the net proceeds of this offering primarily for expansion of sales and distribution network in the strategically selected markets, research and development, and working capital and general corporate matters.
• The company generated revenue of $5.85 million for the six months ended June 30, 2024, of which 44% were from respiratory diseases and COVID-19 related products.
• For the fiscal years ended December 31, 2023 and 2022, the company generated revenue of $6.71 million and $23.54 million, respectively, of which 60% and 99% were from respiratory diseases and COVID-19 related products.
• The company has significant customer concentration, with three customers accounting for nearly 82% of total revenues for the six months ended June 30, 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company is pursuing an IPO and has growth plans, it also faces challenges such as declining COVID-19 related revenue and customer concentration. The sentiment is neutral overall.

Positives

• The supply agreement ensures a consistent source of products for Anbio's distribution.
• The IPO will provide capital for expansion and research and development.
• The company has a diversified global customer portfolio.
• The company has a comprehensive range of IVD products to meet the growing demand in the POCT and OTC market.
• The company has a experienced and proven management team.

Negatives

• The company's revenue is heavily reliant on respiratory diseases and COVID-19 related products, which may decline as the pandemic subsides.
• The company has significant customer concentration, making it vulnerable to the loss of key customers.
• The company has a relatively short operating history compared to some of its established competitors.

Risks

• Geopolitical risks may adversely impact economic conditions, increase market volatility, cause operational disruption to us and impact our strategic plans, which could have adverse effects on our business and its profitability.
• The company may not succeed in promoting and sustaining its brand, which could have an adverse effect on its future growth and business.
• The company's businesses depend on key management executives and professional staff, and its business may suffer if it is unable to recruit and retain them.
• The company may incur losses or experience disruption of its operations as a result of unforeseen or catastrophic events, including pandemics, terrorist attacks, or natural disasters.
• The company's corporate actions will be substantially controlled by its Class B shareholders, CVC Investment and Northwestern Investment, which will have the ability to control or exert significant influence over important corporate matters that require approval of shareholders, which may deprive you of an opportunity to receive a premium for your Class A Ordinary Shares and materially reduce the value of your investment.
• There has been no public market for the company's Class A Ordinary Shares prior to this offering, and you may not be able to resell our Class A Ordinary Shares at or above the price you paid, or at all.
• Because the company's initial public offering price is substantially higher than its pro forma net tangible book value per share, you will experience immediate and substantial dilution.
• There is uncertainty as to the enforceability in the Cayman Islands of judgments predicated upon the civil liability provisions of the securities laws of the United States or any state in the United States. Therefore, certain judgments obtained against us by our shareholders may be difficult to enforce in such jurisdiction.
• There can be no assurance that the company will not be a passive foreign investment company, or PFIC, for United States federal income tax purposes for any taxable year, which could subject United States investors in our Class A Ordinary Shares to significant adverse United States income tax consequences.

Future Outlook

The company expects to finance its operations and working capital needs from part of the net proceeds of the initial public offering and cash generated through operations. The company believes that its current levels of cash, combined with the net proceeds from this offering, will be sufficient to meet its anticipated cash needs for its operations and expansion plans for at least the next 12 months.

Industry Context

The company operates in the competitive in vitro diagnostics (IVD) market, which is characterized by rapid technological developments and evolving industry standards. The company faces competition from established and new market participants, including Abbott Laboratories, Roche, and Siemens.

Comparison to Industry Standards

• The global immunoassays market is highly fragmented.
• Abbott Laboratories, Roche, Siemens, QuidelOrtho, Thermo Fisher Scientific, and Danaher Corporation are market leaders and account for more than 60% of the immunoassays market.
• Smaller market players include, Werfen, R&D Systems, Maccura Biotechnology Co. Ltd., Diatron, Acon, and DaAn Gene Co. Ltd.

Management Changes

Related Party Transactions

• Our former CFO, Richard Chen, is one of the partners of CLC LLP (hereafter CLC). CLC provided accounting services to our company from late 2021. 2021 and 2022 accounting fee incurred was $97,592.34. For yearend December 31, 2023, the total accounting fee incurred to CLC is $54,746.

Stakeholder Impact

• Shareholders will be impacted by the potential dilution from the IPO and the control exerted by Class B shareholders.
• Employees may be affected by the company's ability to recruit and retain key personnel.
• Customers may benefit from the company's expansion of sales and distribution network and development of new products.
• Suppliers may be impacted by the company's ability to maintain relationships and manage costs.

Next Steps

• The company plans to list its Class A Ordinary Shares on the Nasdaq Global Market under the symbol NNNN.
• The company intends to use the net proceeds of this offering primarily for expansion of sales and distribution network in the strategically selected markets, research and development, and working capital and general corporate matters.

Key Dates

Keywords

IPO, supply agreement, medical devices, in vitro diagnostics, Class A Ordinary Shares, Class B Ordinary Shares, revenue, COVID-19, Anbio Biotechnology, financials